22.728 articles found

Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?

Ambermoon P, Carter A, Hall W, Dissanayaka N, O'Sullivan J.

Addiction · 2011-07-27

DOI: 10.1111/j.1360-0443.2011.03511.xPMID: 21793971

Malnutritional neuropathy under intestinal levodopa infusion.

Klostermann F, Jugel C, Müller T, Marzinzik F.

J Neural Transm (Vienna) · 2011-07-24

DOI: 10.1007/s00702-011-0689-3PMID: 21786115

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Armentero MT, Pinna A, Ferré S, Lanciego JL, Müller CE, Franco R.

Pharmacol Ther · 2011-07-23

DOI: 10.1016/j.pharmthera.2011.07.004PMID: 21810444

TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS

HOWSON PATRICK ALEXANDER.

· 2011-07-20

The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.

Geiser E, Kaelin-Lang A.

Behav Brain Res · 2011-07-20

DOI: 10.1016/j.bbr.2011.07.019PMID: 21787806

Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies.

Facecchia K, Fochesato LA, Ray SD, Stohs SJ, Pandey S.

J Toxicol · 2011-07-14

DOI: 10.1155/2011/683728PMID: 21785590

Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stöffler A, Streffer J, Berg D.

J Neural Transm (Vienna) · 2011-07-14

DOI: 10.1007/s00702-011-0682-xPMID: 21755462

A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection.

L'episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, Caniglia S, Morale MC, Pluchino S, Marchetti B.

Mol Neurodegener · 2011-07-13

DOI: 10.1186/1750-1326-6-49PMID: 21752258

Neurosurgical convection-enhanced delivery of treatments for Parkinson's disease.

Lam MF, Thomas MG, Lind CR.

J Clin Neurosci · 2011-07-13

DOI: 10.1016/j.jocn.2011.01.012PMID: 21745745

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK.

Mov Disord · 2011-07-13

DOI: 10.1002/mds.23861PMID: 21755537

D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease.

Gelfin E, Kaufman Y, Korn-Lubetzki I, Bloch B, Kremer I, Javitt DC, Heresco-Levy U.

Int J Neuropsychopharmacol · 2011-07-07

DOI: 10.1017/s1461145711001015PMID: 21733283

A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.

Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, Wood E, Morris S.

J Med Econ · 2011-07-06

DOI: 10.3111/13696998.2011.598201PMID: 21728911